

Stem Cells International, 2018, vol.2018

---

# Influence of genetically modified human umbilical cord blood mononuclear cells on the expression of schwann cell molecular determinants in spinal cord injury

Kazan Federal University, 420008, Kremlevskaya 18, Kazan, Russia

---

## Abstract

Copyright © 2018 L. R. Galieva et al. Spinal cord injury (SCI) unavoidably results in death of not only neurons but also glial cells. In particular, the death of oligodendrocytes leads to impaired nerve impulse conduction in intact axons. However, after SCI, the Schwann cells (SCs) are capable of migrating towards an area of injury and participating in the formation of functional myelin. In addition to SCI, cellbased therapy can influence the migration of SCs and the expression of their molecular determinants. In a number of cases, it can be explained by the ability of implanted cells to secrete neurotrophic factors (NTFs). Genetically modified stem and progenitor cells overexpressing NTFs have recently attracted special attention of researchers and are most promising for the purposes of regenerative medicine. Therefore, we have studied the effect of genetically modified human umbilical cord blood mononuclear cells on the expression of SC molecular determinants in SCI.

<http://dx.doi.org/10.1155/2018/4695275>

---

## References

- [1] S. X. Zhang, F. Huang, M. Gates, and E. G. Holmberg, "Role of endogenous Schwann cells in tissue repair after spinal cord injury," *Neural Regeneration Research*, vol. 8, no. 2, pp. 177-185, 2013.
- [2] C. Bachelin, F. Lachapelle, and C. Girard, "Efficient myelin repair in the macaque spinal cord by autologous grafts of Schwann cells," *Brain*, vol. 128, no. 3, pp. 540-549, 2005.
- [3] J. F. Talbott, Q. Cao, G. U. Enzmann et al., "Schwann cell-like differentiation by adult oligodendrocyte precursor cells following engraftment into the demyelinated spinal cord is BMPdependent," *Glia*, vol. 54, no. 3, pp. 147-159, 2006.
- [4] M. Zawadzka, L. E. Rivers, S. P. Fancy et al., "CNS-resident glial progenitor/stem cells produce Schwann cells as well as oligodendrocytes during repair of CNS demyelination," *Cell Stem Cell*, vol. 6, no. 6, pp. 578-590, 2010.
- [5] K. Bartus, J. Galino, and N. D. James, "Neuregulin-1 controls an endogenous repair mechanism after spinal cord injury," *Brain*, vol. 139, no. 5, pp. 1394-1416, 2016.
- [6] Q. Cao, X. M. Xu, W. H. Devries et al., "Functional recovery in traumatic spinal cord injury after transplantation of multineurotrophin-expressing glial-restricted precursor cells," *The Journal of Neuroscience*, vol. 25, no. 30, pp. 6947-6957, 2005.
- [7] T. Iwase, C. G. Jung, H. Bae, M. Zhang, and B. Soliven, "Glial cell line-derived neurotrophic factor-induced signaling in Schwann cells," *Journal of Neurochemistry*, vol. 94, no. 6, pp. 1488-1499, 2005.
- [8] L. Zhang, Z. Ma, G. M. Smith et al., "GDNF-enhanced axonal regeneration and myelination following spinal cord injury is mediated by primary effects on neurons," *Glia*, vol. 57, no. 11, pp. 1178-1191, 2009.
- [9] E. Storkebaum, D. Lambrechts, and P. Carmeliet, "VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection," *Bioessays*, vol. 26, no. 9, pp. 943-954, 2004.

- [10] C. T. Chen, N. H. Foo, W. S. Liu, and S. H. Chen, "Infusion of human umbilical cord blood cells ameliorates hind limb dysfunction in experimental spinal cord injury through antiinflammatory, vasculogenic and neurotrophic mechanisms," *Pediatrics and Neonatology*, vol. 49, no. 3, pp. 77-83, 2008.
- [11] V. R. Dasari, K. K. Veeravalli, A. J. Tsung et al., "Neuronal apoptosis is inhibited by cord blood stem cells after spinal cord injury," *Journal of Neurotrauma*, vol. 26, no. 11, pp. 2057-2069, 2009.
- [12] Y. O. Mukhamedshina, E. E. Garanina, G. A. Masgutova et al., "Assessment of glial scar, tissue sparing, behavioral recovery and axonal regeneration following acute transplantation of genetically modified human umbilical cord blood cells in a rat model of spinal cord contusion," *PLoS One*, vol. 11, no. 3, article e0151745, 2016.
- [13] J. Pomyje, J. Zivný, L. Sefc, M. Plasilová, R. Pytlík, and E. Necas, "Expression of genes regulating angiogenesis in human circulating hematopoietic cord blood CD34+/CD133 + cells," *European Journal of Haematology*, vol. 70, no. 3, pp. 143-150, 2003.
- [14] L. Bracci-Laudiero, D. Celestino, G. Starace et al., "CD34-positive cells in human umbilical cord blood express nerve growth factor and its specific receptor TrkA," *Journal of Neuroimmunology*, vol. 136, no. 1-2, pp. 130-139, 2003.
- [15] Y. O. Mukhamedshina, G. F. Shaymardanova, E. E. Garanina et al., "Adenoviral vector carrying glial cell-derived neurotrophic factor for direct gene therapy in comparison with human umbilical cord blood cell-mediated therapy of spinal cord injury in rat," *Spinal Cord*, vol. 54, no. 5, pp. 347-359, 2016.
- [16] Y. O. Mukhamedshina, Z. E. Gilazieva, S. S. Arkhipova et al., "Electrophysiological, morphological, and ultrastructural features of the injured spinal cord tissue after transplantation of human umbilical cord blood mononuclear cells genetically modified with the VEGF and GDNF genes," *Neural Plasticity*, vol. 2017, Article ID 9857918, 12 pages, 2017.
- [17] Y. Sato, M. Kimura, C. Yasuda et al., "Evidence for the presence of major peripheral myelin glycoprotein P0 in mammalian spinal cord and a change of its glycosylation state during aging," *Glycobiology*, vol. 9, no. 7, pp. 655-660, 1999.
- [18] K. R. Jessen and R. Mirsky, "The origin and development of glial cells in peripheral nerves," *Nature Reviews. Neuroscience*, vol. 6, no. 9, pp. 671-682, 2005.
- [19] M. Escurat, K. Djabali, M. Gumpel, F. Gros, and M. M. Portier, "Differential expression of two neuronal intermediate filament proteins, peripherin and the low-molecular-mass neurofilament protein (NF-L), during the development of the rat," *The Journal of Neuroscience*, vol. 10, no. 3, pp. 764-784, 1990.
- [20] W. T. Clarke, B. Edwards, K. J. A. McCullagh et al., "Syncoilin modulates peripherin filament networks and is necessary for large-calibre motor neurons," *Journal of Cell Science*, vol. 123, no. 15, pp. 2543-2552, 2010.
- [21] X. Y. Song, J. H. Zhong, X. Wang, and X. F. Zhou, "Suppression of p75NTR does not promote regeneration of injured spinal cord in mice," *Journal of Neuroscience*, vol. 24, no. 2, pp. 542-546, 2004.
- [22] S. Deand J. E. Turman Jr, "Krox-20 gene expression: influencing hindbrain-craniofacial developmental interactions," *Archives of Histology and Cytology*, vol. 68, no. 4, pp. 227-234, 2005.
- [23] T. Hagg and M. Oudega, "Degenerative and spontaneous regenerative processes after spinal cord injury," *Journal of Neurotrauma*, vol. 23, no. 3-4, pp. 263-280, 2006.
- [24] A. A. Lavdas, F. Papastefanaki, D. Thomaidou, and R. Matsas, "Schwann cell transplantation for CNS repair," *Current Medicinal Chemistry*, vol. 15, no. 2, pp. 151-160, 2008.
- [25] V. Zujovic, C. Bachelin, and A. Baron-Van Evercooren, "Remyelination of the central nervous system: a valuable contribution from the periphery," *The Neuroscientist*, vol. 13, no. 4, pp. 383-391, 2007.
- [26] L. Jasmin, G. Janni, T. M. Moallem, D. A. Lappi, and P. T. Ohara, "Schwann cells are removed from the spinal cord after effecting recovery from paraplegia," *The Journal of Neuroscience*, vol. 20, no. 24, pp. 9215-9223, 2000.
- [27] M. Dezawa and E. Adachi-Usami, "Role of Schwann cells in retinal ganglion cell axon regeneration," *Progress in Retinal and Eye Research*, vol. 19, no. 2, pp. 171-204, 2000.
- [28] J. K. Kim, H. J. Lee, and H. T. Park, "Two faces of Schwann cell dedifferentiation in peripheral neurodegenerative diseases: pro-demyelinating and axon-preservative functions," *Neural Regeneration Research*, vol. 9, no. 22, pp. 1952-1954, 2014.
- [29] H. J. Lee, Y. K. Shin, and H. T. Park, "Mitogen activated protein kinase family proteins and c-jun signaling in injuryinduced Schwann cell plasticity," *Experimental neurobiology*, vol. 23, no. 2, pp. 130-137, 2014.
- [30] S. X. Zhang, F. Huang, M. Gates, J. White, and E. G. Holmberg, "Histological repair of damaged spinal cord tissue from chronic contusion injury of rat: a LM observation," *Histology and Histopathology*, vol. 26, no. 1, pp. 45-58, 2011.
- [31] S. Britsch, D. E. Goerich, D. Riethmacher et al., "The transcription factor Sox10 is a key regulator of peripheral glial development," *Genes & Development*, vol. 15, no. 1, pp. 66-78, 2001.
- [32] J. Qin, L. Wang, L. Zheng et al., "Concentrated growth factor promotes Schwann cell migration partly through the integrin  $\beta$ 1-mediated activation of the focal adhesion kinase pathway," *International Journal of Molecular Medicine*, vol. 37, no. 5, pp. 1363-1370, 2016.

- [33] E. S. Anton, G. Weskamp, L. F. Reichardt, and W. D. Matthew, "Nerve growth factor and its low-affinity receptor promote Schwann cell migration," *Proceedings of the National Academy of Sciences*, vol. 91, no. 7, pp. 2795-2799, 1994.
- [34] J. Yamauchi, J. R. Chan, and E. M. Shooter, "Neurotrophins regulate Schwann cell migration by activating divergent signaling pathways dependent on rho GTPases," *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 23, pp. 8774-8779, 2004.
- [35] A. Blesch and M. H. Tuszynski, "Transient growth factor delivery sustains regenerated axons after spinal cord injury," *The Journal of Neuroscience*, vol. 27, no. 39, pp. 10535-10545, 2007.
- [36] M. Sondell, G. Lundborg, and M. Kanje, "Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system," *The Journal of Neuroscience*, vol. 19, no. 14, pp. 5731-5740, 1999.
- [37] Y. O. Mukhamedshina, G. F. Shaymardanova, A. R. Muhitov et al., "Survival and differentiation of endogenous schwann cells migrating into spinal cord under the influence of neurotrophic factors," *Gene and Cells*, vol. 7, no. 3, pp. 125-129, 2012.
- [38] G. Lemke and R. Axel, "Isolation and sequence of a cDNA encoding the major structural protein of peripheral myelin," *Cell*, vol. 40, no. 3, pp. 501-508, 1985.
- [39] A. Antonellis, M. Y. Dennis, G. Burzynski et al., "A rare myelin protein zero (MPZ) variant alters enhancer activity in vitro and in vivo," *PloS One*, vol. 5, no. 12, article e14346, 2010.
- [40] C. S. Gillespie, B. D. Trapp, D. R. Colman, and P. J. Brophy, "Distribution of myelin basic protein and P2 mRNAs in rabbit spinal cord oligodendrocytes," *Journal of Neurochemistry*, vol. 54, no. 5, pp. 1556-1561, 1990.
- [41] M. M. Watila and S. A. Balarabe, "Molecular and clinical features of inherited neuropathies due to PMP22 duplication," *Journal of the Neurological Sciences*, vol. 355, no. 1-2, pp. 18-24, 2015.
- [42] J. Li, B. Parker, C. Martyn, C. Natarajan, and J. Guo, "The PMP22 gene and its related diseases," *Molecular Neurobiology*, vol. 47, no. 2, pp. 673-698, 2013.
- [43] A. Moghieb, H. M. Bramlett, J. H. Das et al., "Differential neuroproteomic and systems biology analysis of spinal cord injury," *Molecular & Cellular Proteomics*, vol. 15, no. 7, pp. 2379-2395, 2016.